Accuray has appointed industry veteran Steve La Neve as chief executive officer, effective immediately, as the company initiates a major operational and strategic overhaul.

La Neve succeeds Suzanne Winter, who is retiring after six years with the Madison, Wisconsin-based radiation therapy company. Winter will stay on in an advisory capacity through the end of November.

The leadership change is part of a wider transformation plan aimed at improving operating margins, increasing organizational agility, and positioning the company for long-term growth. Most of the changes are expected to roll out during the current fiscal year.
Accuray expects to report total revenue of $92.5 million to $94 million for the first quarter of fiscal 2026. While service revenue was ahead of plan, product revenue underperformed in EIMEA and China. Adjusted EBITDA for the quarter is expected to be approximately negative $4 million.

The company plans to release full financial results on November 5.

La Neve brings more than four decades of experience in medical technology. His previous roles include senior leadership positions at Globus Medical, Bone Biologics Corporation, Becton Dickinson, and Medtronic.

Accuray also named Steven F. Mayer as transformation board sponsor. Mayer, who joined the board in June, will work closely with La Neve and the executive team to guide the transformation. He previously held senior roles at Cerberus Capital Management and most recently led a restructuring at global healthcare company Grifols.

"I'm excited to partner with Steve La Neve and the board to accelerate Accuray's transformation," Mayer said. "We are acting decisively to align with strategic objectives, strengthen operations and deliver meaningful performance gains."

The company also announced the nomination of Chan W. Galbato to its board of directors. Galbato, a senior advisor to Barington Capital Group and Alvarez & Marsal, has held executive roles at companies including Cerberus, Albertsons, and GE.

Rad Oncology Homepage